Summary by Moomoo AI
Merck & Co., Inc. (Merck) reported a robust financial performance in the third quarter of 2024, with worldwide sales reaching $16.7 billion, a 4% increase compared to the same period in 2023. Excluding the impact of foreign exchange, sales grew by 7%. The U.S. market saw a 13% rise in sales, contributing significantly to the overall growth. The oncology franchise, particularly Keytruda and Welireg, drove the sales increase, along with the cardiovascular franchise's new launch, Winrevair. However, sales were partially offset by declines in the diabetes and virology franchises, with Januvia and Janumet experiencing reduced sales due to competitive pressures and pricing challenges. Merck's Animal Health segment also saw a 6% increase in sales, attributed to new product launches and higher pricing. The company's...Show More
